Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Delving into Gilead Sciences's Background Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

with a focus on expanding access to Gilead’s therapies and driving sustainable growth. Petrelli has experience in the ...

The firm decreased its portfolio allocation in GILD by 9.71% over the last quarter. Gilead Sciences Background Information ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

Carlos Lozada is an Opinion columnist and a co-host of the weekly “Matter of Opinion” podcast for The Times, based in ...

This was compared to the background incidence, which was determined when screening ... according to study data on Gilead's website. Overall, Kelley said lenacapavir was safe and well-tolerated despite ...

This diverse educational background equipped me with a unique blend of technical, scientific, and management skills, which ...

This was compared to the background incidence ... according to study data on Gilead's website. Safety data Overall, Kelley said lenacapavir was safe and well-tolerated despite some side effects ...

According to a press statement from Gilead on the results of a research ... "When compared to the background HIV incidence... lenacapavir reduced HIV infections by 96%." She added, "It's no ...